ResMed is taking a “smart devices” and Big Data approach to further entrench itself as one of the two leading players in the global obstructive sleep apnea, or OSA, market. With cloud ...

Oct 24 (Reuters) - ResMed (RMD.N), opens new tab beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its devices used for sleep apnea treatment. Shares of the ...

2030 ambition to help more than 500 million people worldwide achieve their full health potential Showcases integration of intelligent products and solutions within the ResMed ecosystem ...

ResMed Inc (NYSE:RMD) reports a robust 11% increase in net revenue year-over-year. Significant growth in Sleep and Breathing Health segment, showcasing an 11% rise in sales. Strong gross margin ...

Residential Care Software Revenue: Increased by 12%. ResMed Inc (NYSE:RMD) reported a strong quarter with an 11% revenue growth, driven by demand for sleep health and breathing health medical devices.